City
Epaper

US FDA clears 1st smartphone app for timely insulin delivery

By IANS | Updated: February 18, 2022 15:30 IST

San Francisco, Feb 18 The US Food and Drug Administration (FDA) has cleared the first smartphone app for ...

Open in App

San Francisco, Feb 18 The US Food and Drug Administration (FDA) has cleared the first smartphone app for insulin delivery on both iOS and Android operating systems.

The move is seen as a big relief for people who prefer not to have insulin pumps out in public settings or attach them to undergarments like bras.

Tandem Diabetes Care, a leading insulin delivery and diabetes technology company, announced that FDA has cleared 'bolus insulin' dosing on the 't:slim X2' insulin pump using the 't:connect' mobile app.

The updated t:connect mobile app is designed to offer insulin pump users the ability to programme and cancel bolus insulin requests through the convenience of their compatible smartphone.

Previously, delivery had to be handled through the pump itself.

"With the improvements in diabetes management provided by Tandem's Control-IQ technology, giving a meal bolus is now the most common reason a person interacts with their pump, and the ability to do so using a smartphone app offers a convenient and discrete solution," said John Sheridan, president and CEO of Tandem Diabetes Care.

The company intends to roll out the mobile bolus feature update throughout the spring in a series of limited launch groups, followed by an expanded launch later this summer.

The mobile app is a secure, user-friendly mobile application that, when paired with the insulin pump, discreetly displays the user's pump information on their personal smartphone.

In addition to the newly-cleared bolus feature, the mobile app displays the last 24 hours of glucose trends, pump status changes, and insulin therapy data, including basal and bolus deliveries and suspensions of insulin delivery.

The app also displays pump alerts and alarms, and it securely uploads data into the cloud-based t:connect web application wirelessly.

"Importantly, the t:slim X2 insulin pump functions independently from the t:connect mobile app, therefore a user always retains the freedom to view pump therapy data, programme requests and cancel bolus insulin requests from their pump," said the company.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: John SheridanfdaUs Food And Drug Administration
Open in App

Related Stories

PunePune: Action to Be Taken Against Use of Calcium Carbide to Ripen Mangoes

MumbaiMumbai: FDA Seizes Medicines Worth Rs 61.95 Lakh from Ghatkopar-Based Drug Firm

MumbaiMumbai: FDA Cracks Down on Adulterated Milk at City Entry Points; Over 1.5 Lakh Litres Inspected

MaharashtraChandrapur Shops Caught Selling Fake Paneer; FDA Seizes 472 Kg of Cheese Analogue

MumbaiMumbai FDA Allows Homeopathy Doctors to Prescribe Allopathic Medicines; IMA Opposes Decision

Technology Realted Stories

TechnologyTech Mahindra headcount drops by 1,757 in Q4

TechnologyCentre extends financial aid to indigenous indoor air purification solution

TechnologyIndia to soon launch safety assessment rating for trucks and heavy vehicles: Nitin Gadkari

TechnologyBroadband subscribers stand at 944.04 million in Feb, tele-density up: TRAI

TechnologyIndia achieves breakthrough in gene therapy for haemophilia: Minister